SCHEMBL11943979

SCHEMBL11943979

CCOCCOc1c(N2CCN(S(=O)(=O)C(C)C)CC2)cnn(-c2cccc(C)c2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ NPBWR1 P48145 3/20 0.40
▸ MCHR1 Q99705 2/20 0.40
▸ POLB P06746 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ NCOA2 Q15596 1/20 0.40
▸ NCOA1 Q15788 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ NCOA3 Q9Y6Q9 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ PAX8 Q06710 1/20 0.39
▸ DCTPP1 Q9H773 2/20 0.39
▸ SLC2A1 P11166 1/20 0.36
▸ SLC2A2 P11168 1/20 0.36
▸ SLC2A3 P11169 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943950 0.92 POLB (0.49) MAPTALDH1A1NPBWR1MCHR1POLB
SCHEMBL11943955 0.92 POLB (0.45) MAPTALDH1A1NPBWR1MCHR1POLB
SCHEMBL11943939 0.90 MAPT (0.52) MAPTALDH1A1MCHR1POLBCYP3A4
SCHEMBL11945090 0.90 MAPT (0.41) MAPTALDH1A1POLBCYP3A4CYP2C19
SCHEMBL11945103 0.87 MAPT (0.41) MAPTALDH1A1NPBWR1MCHR1POLB
SCHEMBL11945118 0.87 POLB (0.44) MAPTALDH1A1NPBWR1MCHR1POLB
SCHEMBL11945068 0.86 MAPT (0.43) MAPTALDH1A1NPBWR1MCHR1POLB
SCHEMBL11945108 0.86 MAPT (0.49) MAPTALDH1A1NPBWR1MCHR1POLB
SCHEMBL11945127 0.85 MAPT (0.38) MAPTALDH1A1NPBWR1MCHR1POLB
SCHEMBL11944797 0.84 POLB (0.47) MAPTALDH1A1NPBWR1MCHR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885NPBWR1 4643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback